CO6150191A2 - Vacuna de influenza - Google Patents
Vacuna de influenzaInfo
- Publication number
- CO6150191A2 CO6150191A2 CO09003056A CO09003056A CO6150191A2 CO 6150191 A2 CO6150191 A2 CO 6150191A2 CO 09003056 A CO09003056 A CO 09003056A CO 09003056 A CO09003056 A CO 09003056A CO 6150191 A2 CO6150191 A2 CO 6150191A2
- Authority
- CO
- Colombia
- Prior art keywords
- composition
- tocopherol
- amount
- total volume
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
1.- Una composición de vacuna de influenza monovalente que comprende una baja cantidad de antígeno de virus de influenza o preparación antigénica de una cepa de virus de influenza, que está asociada con una pandemia o tiene el potencial de estar asociada con una pandemia, en combinación con un adyuvante, en donde la baja cantidad de antígeno no excede 15 µg de hemaglutinina (HA) por dosis, y en donde el adyuvante es una emulsión de aceite en agua que comprende un aceite metabolizable, un esterol o un tocoferol, y un agente de emulsificación. 2.- Una composición tal como se describe en la reivindicación 1, caracterizada porque el tocoferol es alfatocoferol. 3.- Una composición tal como se describe en la reivindicación 1 o la reivindicación 2, caracterizada porque el aceite metabolizable es escualeno. 4.- Una composición tal como se describe en cualesquiera de las reivindicaciones de la 1 a la 3, caracterizada porque el aceite metabolizable está presente en una cantidad de 0.5% a 20% del volumen total de la composición inmunogénica. 5.- Una composición tal como se describe en cualesquiera de las reivindicaciones de la 1 a la 4, caracterizada porque el aceite metabolizable está presente en una cantidad de 1.0% a 10% del volumen total de la composición inmunogénica.6.- Una composición tal como se describe en cualesquiera de las reivindicaciones de la 1 a la 5, caracterizada porque el aceite metabolizable está presente en una cantidad de 2.0% a 6.0% del volumen total de la composición inmunogénica.7.- Una composición tal como se describe en cualesquiera de las reivindicaciones de la 1 a la 6, caracterizada porque el tocoferol o alfa-tocoferol está presente en una cantidad de 1.0% a 20% del volumen total de la composición inmunogénica.8.- Una composición tal como se describe en cualesquiera de las reivindicaciones de la 1 a la 7, caracterizada porque el tocoferol o alfa-tocoferol está presente en una cantidad de 1.0% a 5.0% del volumen total de la composición inmunogénica.9.- Una composición tal como se describe en cualesquiera de las reivindicaciones de la 1 a la 8, caracterizada porque la proporción de escualeno: tocoferol o escualeno: alfa tocoferol es igual o menor a 1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83143706P | 2006-07-17 | 2006-07-17 | |
| GB0618195A GB0618195D0 (en) | 2006-09-15 | 2006-09-15 | Influenza vaccine |
| GB0619090A GB0619090D0 (en) | 2006-09-27 | 2006-09-27 | Influenza vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6150191A2 true CO6150191A2 (es) | 2010-04-20 |
Family
ID=37909516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09003056A CO6150191A2 (es) | 2006-07-17 | 2009-01-15 | Vacuna de influenza |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9278127B2 (es) |
| EP (1) | EP2043682B1 (es) |
| JP (1) | JP5639760B2 (es) |
| KR (1) | KR101696727B1 (es) |
| CO (1) | CO6150191A2 (es) |
| CR (1) | CR10559A (es) |
| EA (1) | EA200900024A1 (es) |
| HR (2) | HRP20140488T1 (es) |
| IL (1) | IL196024A0 (es) |
| MA (1) | MA30624B1 (es) |
| MX (1) | MX2009000660A (es) |
| NO (1) | NO20090062L (es) |
| PL (1) | PL2043682T3 (es) |
| WO (1) | WO2008009309A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| JP5869744B2 (ja) | 2005-03-23 | 2016-02-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｃｄ４ｔ細胞および／または改善された記憶ｂ細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用 |
| CN101500603A (zh) | 2006-06-15 | 2009-08-05 | 诺华有限公司 | 节省佐剂的多剂量流感疫苗接种方案 |
| KR101696727B1 (ko) | 2006-07-17 | 2017-01-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 인플루엔자 백신 |
| TW200908994A (en) | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| EP2589392B1 (en) | 2008-03-05 | 2016-11-30 | Sanofi Pasteur | Process for stabilizing an adjuvant containing vaccine composition |
| EP2268309B1 (en) | 2008-03-18 | 2015-01-21 | Novartis AG | Improvements in preparation of influenza virus vaccine antigens |
| US9421251B2 (en) | 2008-06-25 | 2016-08-23 | Novartis Ag | Rapid responses to delayed booster immunisations |
| AU2015203072B2 (en) * | 2009-02-10 | 2017-05-25 | Seqirus UK Limited | Influenza vaccine regimens for pandemic-associated strains |
| US20120093859A1 (en) | 2009-02-10 | 2012-04-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
| JP2013522231A (ja) * | 2010-03-11 | 2013-06-13 | イミューン デザイン コーポレイション | インフルエンザのためのワクチン |
| US20120107354A1 (en) * | 2010-10-30 | 2012-05-03 | George Dacai Liu | Viral vaccine and process for preparing the same |
| EP2578974A1 (en) | 2011-10-05 | 2013-04-10 | Sanofi Pasteur Sa | Process line for the production of freeze-dried particles |
| GB201205189D0 (en) | 2012-03-23 | 2012-05-09 | Glaxosmithkline Biolog Sa | Novel medical use |
| EP3055412B1 (en) | 2013-10-07 | 2020-09-02 | Seqirus UK Limited | Treated filter |
| CA3000093C (en) | 2014-07-21 | 2019-07-09 | Sanofi Pasteur Sa | Liquid feeding device for the generation of droplets |
| KR101729387B1 (ko) | 2015-04-17 | 2017-04-21 | 경희대학교 산학협력단 | 곤충세포 발현시스템을 이용한 인플루엔자 백신 소재 ｍ1-ｍ2-ｎａ-ｈａ 바이러스 유사 입자의 제조방법 |
| CA2990635A1 (en) * | 2015-06-24 | 2016-12-29 | Sanofi Pasteur, Inc. | Methods of use of influenza vaccine for prevention of pneumonia |
| GB201710414D0 (en) | 2017-06-29 | 2017-08-16 | Univ Nottingham | Chemotherapy |
| WO2019143955A1 (en) * | 2018-01-22 | 2019-07-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly protective inactivated influenza virus vaccine |
| US11435351B2 (en) * | 2018-04-18 | 2022-09-06 | Biomadison, Inc. | Methods for determining vaccine potency |
| KR102103638B1 (ko) * | 2018-06-01 | 2020-04-22 | 연세대학교 산학협력단 | 저온 적응된 약독화 바이러스를 이용한 유니버설 독감 백신 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| GB8300467D0 (en) | 1983-01-08 | 1983-02-09 | Wellcome Found | Equine influenza |
| US5376369A (en) | 1987-11-03 | 1994-12-27 | Syntex (U.S.A.) Inc. | Vaccine adjuvant |
| GB8821049D0 (en) | 1988-09-08 | 1988-10-05 | Health Lab Service Board | Method & composition for treatment & prevention of viral infections |
| EP0382271B1 (en) | 1989-02-04 | 1994-12-21 | Akzo Nobel N.V. | Tocols as adjuvant in vaccine |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5969109A (en) | 1990-02-28 | 1999-10-19 | Bona; Constantin | Chimeric antibodies comprising antigen binding sites and B and T cell epitopes |
| US5149531A (en) | 1990-06-27 | 1992-09-22 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza |
| GB9105992D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
| MA22842A1 (fr) | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
| DE4220757A1 (de) | 1992-06-24 | 1994-01-05 | Schering Ag | Derivate in der Vitamin D-Reihe mit Modifikationen in der 20-Position, Verfahren zu ihrer Herstellung, Zwischenprodukte für dieses Verfahren, diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
| CN1124013A (zh) | 1993-02-19 | 1996-06-05 | 史密丝克莱恩比彻姆公司 | 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物 |
| CA2156525A1 (en) | 1993-02-19 | 1994-09-01 | Susan Dillon | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
| US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
| AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| JP3836874B2 (ja) | 1994-02-24 | 2006-10-25 | ノババックス インコーポレイテッド | 免疫アジュバントとして少ラメラ脂質小胞を含むワクチン |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US5916879A (en) | 1996-11-12 | 1999-06-29 | St. Jude Children's Research Hospital | DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| DE69838992T2 (de) | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Öl-in-Wasser Emulsionen mit Saponinen |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US6838269B1 (en) | 1998-04-15 | 2005-01-04 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
| WO1999056776A2 (en) | 1998-05-07 | 1999-11-11 | Corixa Corporation | Adjuvant composition and methods for its use |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| AT407958B (de) | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
| EP1574210B1 (en) | 1999-02-26 | 2016-04-06 | Novartis Vaccines and Diagnostics, Inc. | Microemulsions with adsorbed macromolecules |
| GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| PL211762B1 (pl) | 2000-01-31 | 2012-06-29 | Smithkline Beecham Biolog | Zastosowanie białka fuzyjnego zawierającego białka HIV Tat i HIV Nef lub polinukleotyd kodujący takie białko, białka lub polinukleotydu HIV gp120, białka lub polinukleotydu SIV Nef, adiuwanta indukującego TH1 zawierającego monofosforylolipid A lub jego pochodną i adiuwanta saponinowego oraz kompozycja szczepionki |
| GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
| EP1201250A1 (en) | 2000-10-25 | 2002-05-02 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Immunogenic compositions comprising liver stage malarial antigens |
| PT1361890E (pt) | 2001-02-23 | 2011-06-07 | Glaxosmithkline Biolog Sa | Formulações vacinais de influenza para distribuição intradérmica |
| MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
| US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
| US6861410B1 (en) | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
| AU2003224819A1 (en) | 2002-04-01 | 2003-10-20 | Euro-Celtique S.A. | Epitope constructs comprising antigen presenting cell targeting mechanisms |
| DE602004020189D1 (de) | 2003-01-30 | 2009-05-07 | Novartis Vaccines & Diagnostic | Adjuvante influenza-vakzine |
| JP5600375B2 (ja) * | 2004-03-09 | 2014-10-01 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | インフルエンザウイルスワクチン |
| US7330082B2 (en) | 2004-08-23 | 2008-02-12 | Texas Instruments Incorporated | Oscillator system, method of providing a resonating signal and a communications system employing the same |
| US20090028903A1 (en) * | 2005-03-23 | 2009-01-29 | Glaxosmithkline Biologicals, S.A. | Novel use |
| JP5869744B2 (ja) | 2005-03-23 | 2016-02-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｃｄ４ｔ細胞および／または改善された記憶ｂ細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用 |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| CA2628152C (en) * | 2005-11-04 | 2016-02-02 | Novartis Vaccines And Diagnostics S.R.L. | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| WO2007052155A2 (en) * | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| US20110180430A1 (en) * | 2005-11-04 | 2011-07-28 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines including cytokine-inducing agents |
| EA014028B1 (ru) * | 2005-11-04 | 2010-08-30 | Новартис Вэксинс Энд Диагностикс Срл | Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| US9101578B2 (en) | 2006-05-01 | 2015-08-11 | Technovax, Inc. | Polyvalent influenza virus-like particle (VLP) compositions |
| KR101696727B1 (ko) * | 2006-07-17 | 2017-01-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 인플루엔자 백신 |
| PL2422810T3 (pl) | 2006-07-17 | 2015-03-31 | Glaxosmithkline Biologicals Sa | Szczepionka przeciw grypie |
| CN101522218B (zh) | 2006-10-12 | 2012-09-26 | 葛兰素史密丝克莱恩生物有限公司 | 包含水包油乳液佐剂的疫苗 |
| TW200908994A (en) | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
| EP2227251A1 (en) * | 2007-12-06 | 2010-09-15 | GlaxoSmithKline Biologicals SA | Influenza composition |
-
2006
- 2006-10-27 KR KR1020097003223A patent/KR101696727B1/ko active IP Right Grant
- 2006-10-27 PL PL06806620T patent/PL2043682T3/pl unknown
- 2006-10-27 JP JP2009519798A patent/JP5639760B2/ja active Active
- 2006-10-27 EP EP06806620.8A patent/EP2043682B1/en active Active
- 2006-10-27 EA EA200900024A patent/EA200900024A1/ru unknown
- 2006-10-27 MX MX2009000660A patent/MX2009000660A/es active IP Right Grant
- 2006-10-27 WO PCT/EP2006/010439 patent/WO2008009309A1/en active Application Filing
-
2008
- 2008-12-18 IL IL196024A patent/IL196024A0/en unknown
-
2009
- 2009-01-06 NO NO20090062A patent/NO20090062L/no not_active Application Discontinuation
- 2009-01-14 CR CR10559A patent/CR10559A/es not_active Application Discontinuation
- 2009-01-15 CO CO09003056A patent/CO6150191A2/es unknown
- 2009-02-04 MA MA31612A patent/MA30624B1/fr unknown
-
2011
- 2011-06-17 US US13/163,002 patent/US9278127B2/en active Active
-
2014
- 2014-05-29 HR HRP20140488TT patent/HRP20140488T1/hr unknown
- 2014-11-19 HR HRP20141122TT patent/HRP20141122T1/hr unknown
-
2016
- 2016-01-15 US US14/996,446 patent/US9943588B2/en active Active
-
2018
- 2018-03-14 US US15/920,519 patent/US10555999B2/en active Active
-
2019
- 2019-12-20 US US16/722,437 patent/US11564984B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200360507A1 (en) | 2020-11-19 |
| IL196024A0 (en) | 2011-08-01 |
| US9278127B2 (en) | 2016-03-08 |
| US20110243987A1 (en) | 2011-10-06 |
| HRP20141122T1 (hr) | 2015-01-02 |
| JP5639760B2 (ja) | 2014-12-10 |
| JP2009543816A (ja) | 2009-12-10 |
| PL2043682T3 (pl) | 2014-09-30 |
| KR20090029851A (ko) | 2009-03-23 |
| EA200900024A1 (ru) | 2009-06-30 |
| KR101696727B1 (ko) | 2017-01-16 |
| US9943588B2 (en) | 2018-04-17 |
| EP2043682A1 (en) | 2009-04-08 |
| EP2043682B1 (en) | 2014-04-02 |
| MA30624B1 (fr) | 2009-08-03 |
| NO20090062L (no) | 2009-02-16 |
| US20190054162A1 (en) | 2019-02-21 |
| HRP20140488T1 (hr) | 2014-07-04 |
| CR10559A (es) | 2009-03-20 |
| US11564984B2 (en) | 2023-01-31 |
| US10555999B2 (en) | 2020-02-11 |
| MX2009000660A (es) | 2009-04-08 |
| WO2008009309A1 (en) | 2008-01-24 |
| US20160256537A1 (en) | 2016-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6150191A2 (es) | Vacuna de influenza | |
| CO6251369A2 (es) | Vacuna de influenza de emulsion de aceite en agua | |
| BRPI0621886A8 (pt) | composição de vacina contra influenza monovalente, kit, método para a produção de uma composição de vacina contra influenza para uma situação pandêmica ou uma situação pré-pandêmica, e, usos de um antígeno de vírus da influenza ou preparação antigênica do mesmo e de um adjuvante em emulsão óleo-em-água, de um antígeno de vírus da influenza pandêmica ou preparação antigênica do antígeno de hemaglutinina do vírus da influenza, de um vírus da influenza pandêmica ou preparação antigênica do mesmo, e de um adjuvante em emulsão óleo-em-água e de um antígeno ou preparação antigênica de uma primeira cepa de influenza | |
| PE20061428A1 (es) | Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl | |
| CR10726A (es) | Vacuna que comprende un adyuvante de emulsion de aceite en agua | |
| CL2016000650A1 (es) | Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento. | |
| PE20151588A1 (es) | Vacuna contra el virus del dengue | |
| PE20140646A1 (es) | Vacuna de virus de dengue inactivado | |
| UA107940C2 (en) | The vaccine composition that includes the saponin-containing adjuvant | |
| CO5540349A2 (es) | Preparacion vacunal de virus de influenza inactivado | |
| BR112015005056A2 (pt) | vacinas de combinação com sorogrupo b meningococcus e d/t/p | |
| BR112015021523A8 (pt) | composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis | |
| AR083361A1 (es) | Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon | |
| BRPI0918806A2 (pt) | composição compreendendo quitosana para administração ocular de vaninas em aves | |
| EA201171033A1 (ru) | Вакцины против гриппа со сниженным количеством сквалена | |
| CL2007002710A1 (es) | Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs. | |
| BRPI0516542A (pt) | composição de vacina eficaz na prevenção ou melhora de infecção pelo vìrus da influenza aviária; método para prevenir ou melhorar a eclosão de infecção pelo vìrus da influenza aviária | |
| BR112021001188A8 (pt) | Composição que contém vacina contra a influenza | |
| BR112013008869A2 (pt) | uso do agente quelante e compostos antimicrobianos peptídeos | |
| CO2023015036A2 (es) | Composición inmunogénica contra la influenza | |
| BR112016012435A8 (pt) | vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2 | |
| BR112014023283A8 (pt) | Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza | |
| BR112012014689A2 (pt) | composição de vacina | |
| CL2013002829A1 (es) | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. | |
| AR106501A1 (es) | Adyuvante y composición de vacuna que lo contiene |